| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -1,785,058 |
| Preferred shares issued as compensation | 11,632 |
| Common shares issued as compensation and for services | 38,250 |
| Warrants granted to scientific advisory board | 135 |
| Depreciation | 130,752 |
| Amortization | 2,068 |
| Prepaid expenses | 14,709 |
| Other assets | -358 |
| Accounts payable | -57,301 |
| Accounts payable - related parties | 79,687 |
| Accrued expenses | 331 |
| Net cash used in operating activities | -1,593,855 |
| Purchase of property and equipment | 84,317 |
| Net cash used in investing activities | -84,317 |
| Net proceeds from sale of common stock | 1,245,319 |
| Net cash provided by financing activities | 1,245,319 |
| Net change in cash and cash equivalents | -432,853 |
| Cash and cash equivalents at beginning of period | 1,558,564 |
| Cash and cash equivalents at end of period | 1,125,711 |
NANOVIRICIDES, INC. (NNVC)
NANOVIRICIDES, INC. (NNVC)